Abstract:Background: We conducted a meta-analysis to evaluate the efficacy of anti-programmed cell death 1 (PD1)/programmed cell death ligand 1 (PD-L1) monotherapy or immunotherapy combined with chemotherapy and further estimated the value of PD-L1 expression in predicting the response from anti-PD-1/PD-L1 treatments as monotherapy or in combination with chemotherapy. Methods: Clinical trial data were searched from electronic databases, which evaluated PD-1/PD-L1 inhibitors in non-small cell lung cancer (NSCLC) and correlated with PD-L1 expression levels. Results: Fifteen randomized-controlled trials involving 10,074 patients were identified. Comparing antiPD-1/PD-L1 monotherapy to chemotherapy, the pooled HR for overall survival (OS) was 0.77 (95% CI: 0.69-0.85, P<0.00001). Subgroup analyses revealed that patients had longer OS at >= 1%, >= 5%, >= 10% and >= 50% PD-L1 expression levels. Patients with higher PD-L1 expression may get increased benefit from PD-1/PD-L1 inhibitors. Moreover, patients with PD-L1 >= 50% had an objective response rate (ORR) improvement from anti-PD-1/PD-L1 therapy (RR = 1.87, 95% CI: 1.27-2.75, P=0.001), but no ORR benefits were observed in patients with PD-L1 expression <1% (RR = 0.82, 95% CI: 0.56-1.22, P=0.33) or 1-49% (RR = 0.80, 95% CI: 0.64-0.98, P=0.03). OS was significantly better in patients receiving second-orthird line treatments (P<0.00001) with PD-L1 >= 1%. The efficacy of PD-1 inhibitors was similar to that of PD-L1 inhibitors, with no significant difference (P=0.63, I-2=0%). Furthermore, immunotherapy combined with chemotherapy had better OS (HR = 0.64, 95% CI: 0.48-0.84, P=0.001) than chemotherapy alone. Subgroup analyses showed that patients benefited from the combined chemo-IO treatment in the first-line setting regardless of PD-L1 expression level. Conclusions: PD-L1 expression may be a valuable predictor of the efficacy of anti-PD-1/PD-L1 monotherapy in certain NSCLC patients. However, the combination of chemotherapy plus immunotherapy significantly improved survival regardless of the PD-L1 expression level in the first-line treatment of NSCLC.

Prognostic Value of Programmed Cell Death-Ligand 1 Expression in Patients with Non-Small-cell Lung Cancer: Evidence from an Updated Meta-Analysis.

The Prognostic and Clinicopathological Significance of PD-L1 Expression in Patients with Diffuse Large B-cell Lymphoma: a Meta-Analysis

Prognostic value of PD-L 1 expression in non-small cell lung cancer : a meta-analysis

Prognostic Value of Programed Death Ligand 1 in Patients with Solid Tumors: A Meta-Analysis

The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients.

The Clinicopathological Significance and Prognostic Value of Programmed Death-Ligand 1 in Prostate Cancer: a Meta-Analysis of 3133 Patients

Prognostic Value of Programmed Cell Death Ligand 1 Expression in Patients with Head and Neck Cancer: A Systematic Review and Meta-Analysis

The Predictive And Prognostic Effects Of Pd-L1 Expression On Tki Treatment And Survival Of Egfr-Mutant Nsclc A Meta-Analysis

The Prognostic Value of Programmed Cell Death Ligand 1 Expression in Non-Hodgkin Lymphoma: a Meta-Analysis

PD-L1 Over-Expression and Survival in Patients with Non-Small Cell Lung Cancer: a Meta-Analysis.

The Association of PD-L1 Expression with the Efficacy of Anti-Pd-1/pd-l1 Immunotherapy and Survival of Non-Small Cell Lung Cancer Patients: a Meta-Analysis of Randomized Controlled Trials

Pd-L1 Expression in Lung Cancer and Its Correlation with Driver Mutations: A Meta-Analysis

Prognostic Significance of PD-L1 Expression in Patients with Head and Neck Squamous Cell Carcinoma

Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients

Association Between PD-L1 Expression and Driver Gene Status in Non-Small-cell Lung Cancer: a Meta-Analysis

The Clinicopathological and Prognostic Significance of PD-L1 Expression in Pancreatic Cancer: A Meta-Analysis

Association of PD-L 1 expression with clinicopathologic features and overall survival in patients with non-small-cell lung cancer

Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis

Expression Of Pd-L1 And Prognosis In Breast Cancer: A Meta-Analysis

PD-L1 Expression and Comprehensive Molecular Profiling Predict Survival in Nonsmall Cell Lung Cancer: A Real-World Study of a Large Chinese Cohort

Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients.